Pacira BioSciences, Inc.
Pacira BioSciences, Inc. (Nasdaq: PCRX) develops and commercializes non-opioid therapies for pain, with products used by healthcare providers to manage postsurgical pain and osteoarthritis-related pain. Its commercial portfolio includes EXPAREL, a long-acting bupivacaine injection for local and regional postsurgical… From the company’s description.
In fiscal 2025, Pacira BioSciences, Inc. reported revenue of $726.41M, up 3.6% from fiscal 2024, and net income of $7.03M. Its operating margin was 2.6%, and operations generated $151.99M in cash. Over the twelve months to Sep 30, 2026, revenue was $743.30M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Pacira BioSciences, Inc. does
In the company’s own words
Pacira BioSciences, Inc. (Nasdaq: PCRX) develops and commercializes non-opioid therapies for pain, with products used by healthcare providers to manage postsurgical pain and osteoarthritis-related pain. Its commercial portfolio includes EXPAREL, a long-acting bupivacaine injection for local and regional postsurgical analgesia; ZILRETTA, an extended-release corticosteroid injection for osteoarthritis knee pain; and iovera°, a handheld device that uses controlled cold to temporarily block pain-transmitting nerves. The company is also developing PCRX-201, a locally administered gene therapy in Phase 2 clinical development for knee osteoarthritis, using its high-capacity adenovirus vector platform. Pacira reports its commercial products together rather than describing separate reportable business segments in the provided business overview. EXPAREL is its flagship product, with 2025 net product sales of $575.1 million, equal to 79% of total revenue. The company acquired Flexion Therapeutics in 2021, adding ZILRETTA, and acquired GQ Bio Therapeutics in 2025, adding gene therapy capabilities.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- BRISBANE, CA
- Fiscal year end
- December
- CIK
- 1396814
- SIC
- 2834
Financial performance, year by year
Fiscal 2011–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Pacira BioSciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Pacira BioSciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Pacira BioSciences, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of Pacira BioSciences, Inc.’s debt, $13.40M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 2.13%, maturing 2029 to 2029.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Pacira BioSciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Pacira BioSciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Pacira BioSciences, Inc.'s last four quarterly filings that the numbers alone won't show?”